Storys zum Thema Protein

Schweizerischer Nationalfonds / Fonds national suisse

The tumour hacker

REVEAL GENOMICS, S.L.

REVEAL GENOMICS®´ BREAKTHROUGH TECHNOLOGY ENTERS THE LIQUID BIOPSY FIELD IN ONCOLOGY

Barcelona, Spain (ots/PRNewswire) - - REVEAL GENOMICS®´ machine learning-based technology applied to ctDNA was able to predict drug response and survival outcome in patients with metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitors. - This new approach provides multi-feature genomic predictors from ctDNA for breast cancer and other types of ...

MC2 Therapeutics

MC2 Therapeutics announces initiation of a Phase 2 clinical trial in CKD-aP

Copenhagen, Denmark (ots/PRNewswire) - - Trial based on the recent breakthrough discovery of a novel treatment paradigm for urea associated skin diseases - First patients dosed in Europe in Phase 2 trial assessing the safety and efficacy of MC2-25 Cream in Chronic Kidney Disease-associated Pruritus (CKD-aP) stages 3-5 patients - MC2-25 Cream has the potential to become ...

MC2 Therapeutics

MC2 Therapeutics announces initiation of a Phase 2 clinical trial in CKD-aP

Copenhagen, Denmark (ots/PRNewswire) - - Trial based on the recent breakthrough discovery of a novel treatment paradigm for urea associated skin diseases - First patients dosed in Europe in Phase 2 trial assessing the safety and efficacy of MC2-25 Cream in Chronic Kidney Disease-associated Pruritus (CKD-aP) stages 3-5 patients - MC2-25 Cream has the potential to become ...

Schweizerischer Nationalfonds / Fonds national suisse

What triggers photoreceptor cell death in a disease leading to blindness?

Bern (ots) - In the common eye disease retinitis pigmentosa, the rods and cones of the retina slowly die. Single cell analysis provides insights into the onset of this process. First night blindness and tunnel vision, then the loss of contrast and colour and, in the worst case, total blindness: this is the typical course of retinitis pigmentosa, a hereditary disease of ...

Schweizerischer Nationalfonds / Fonds national suisse

Cancerous tumours: how likely are they to metastasise?

Bern (ots) - A very aggressive type of cancer has provided a team of researchers supported by the Swiss National Science Foundation with an answer to the question of which tumour cells are at risk of spreading. Cancer treatment is sometimes complicated by the heterogeneity of the cells that form the tumour mass. The problem is how to identify the few cells that are capable of triggering metastases. Thanks to work carried ...

Schweizerischer Nationalfonds / Fonds national suisse

Novel antibiotic deceives bacteria through mimicry

Bern (ots) - Most antibiotics need to penetrate their target bacteria. But Darobactin, a newly discovered compound, is much too large to do so. Nonetheless, it kills many antibiotic-resistant pathogens - by exploiting a tiny weak spot on their surface. Basel researchers have now revealed the amazing mechanism at play and thereby opened the door to developing completely new medicines. An increasing number of bacterial ...

Schweizerischer Nationalfonds / Fonds national suisse

How bacteria sleep through antibiotic attacks

Bern (ots) - Bacteria can survive antibiotic treatment even without antibiotic resistance by slowing down their metabolism and going into a type of deep sleep. A research team funded by the Swiss National Science Foundation reveals the changes bacteria undergo to reach this "persister" state. Resistant bacteria evade the effects of antibiotics by becoming less susceptible, for example by breaking the drugs down. But some ...

Swiss Rockets AG

Swiss Rockets AG announces the founding of ROCKETVAX for the development of a next-generation SARS-CoV-2 vaccine

EvoBiotiX

EvoBiotiX collaborates with Boehringer Ingelheim and the University of Salzburg on naturally derived Extracellular Vesicles (EVs)

Salzburg/Melide(CH) (ots) - Swiss Biotech EvoBiotiX SA today announced a multi-year collaboration with Boehringer Ingelheim in the field of naturally derived EVs. A significant part of this program will fund research of the drug delivery potential of naturally derived EVs in the group of Prof. Meisner-Kober at the ...

Avectas

Avectas and UC Davis Collaborate on Cell Engineering Technology

Dublin (ots/PRNewswire) - Collaboration will advance Avectas' cell engineering technology leveraging UC Davis' world-class cell membrane characterisation expertise Avectas today announced that it has entered into a collaborative agreement with The Simon Laboratory at UC Davis, California, USA (UCD) to engage in the characterisation of cells engineered with Avectas' proprietary, non-viral SOLUPORE(TM) cell engineering ...

Avectas

Avectas Announces Issuance of U.S. Patent for Cell Engineering Technology by the U.S. Patent and Trademark Office

Dublin (ots/PRNewswire) - Avectas announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 10,612,042, which is central to the company's cell engineering technology, Solupore® and expands Avectas' global Intellectual Property portfolio. This patent covers an approach for ...

Abcam plc

Abcam Announces Successful Acquisition of Expedeon's Proteomics and Immunology Business, Enhancing Its Conjugation Capability

Cambridge, England (ots/PRNewswire) - - Includes leading protein conjugation technologies and industry brands Lightning-Link® and CaptSure(TM) - Opportunity to combine Expedeon and Abcam's technologies to create new products to support research and diagnostic development Abcam plc, a global innovator in life ...

Schweizerischer Nationalfonds / Fonds national suisse

Speeding up genetic diagnosis of Huntington's disease

Bern (ots) - Elongated segments of DNA cause Huntington's disease and certain other disorders of the brain. Researchers funded by the SNSF have developed a method to determine the length of the mutated genes quickly and easily. People with Huntington's disease suffer from jerky body movements and decreasing mental abilities. The condition usually leads to death 15-20 years after diagnosis. The cause of the disease is a ...

Merck Healthcare Germany GmbH

Merck in Agreement With Cyclica for AI-augmented Screening Platform to Expand Research Capabilities

Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or UK - Agreement to screen discovery and early development compounds using artificial intelligence and computational biophysics - Cloud-based in silico platform that screens small molecules to determine polypharmacological ...